389 related articles for article (PubMed ID: 20961907)
1. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.
Hantz S; Garnier-Geoffroy F; Mazeron MC; Garrigue I; Merville P; Mengelle C; Rostaing L; Saint Marcoux F; Essig M; Rerolle JP; Cotin S; Germi R; Pillet S; Lebranchu Y; Turlure P; Alain S;
J Antimicrob Chemother; 2010 Dec; 65(12):2628-40. PubMed ID: 20961907
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
3. Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study.
Campos AB; Ribeiro J; Pinho Vaz C; Campilho F; Branca R; Campos A; Baldaque I; Medeiros R; Boutolleau D; Sousa H
Antiviral Res; 2017 Feb; 138():86-92. PubMed ID: 27887982
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
[TBL] [Abstract][Full Text] [Related]
5. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.
Boivin G; Goyette N; Gilbert C; Covington E
J Med Virol; 2005 Nov; 77(3):425-9. PubMed ID: 16173018
[TBL] [Abstract][Full Text] [Related]
6. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V
J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520
[TBL] [Abstract][Full Text] [Related]
8. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
10. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
[TBL] [Abstract][Full Text] [Related]
11. The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations.
Choi SH; Hwang JY; Park KS; Kim Y; Lee SH; Yoo KH; Kang ES; Ahn JH; Sung KW; Koo HH; Kim YJ
Transpl Infect Dis; 2014 Dec; 16(6):919-29. PubMed ID: 25405808
[TBL] [Abstract][Full Text] [Related]
12. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
[TBL] [Abstract][Full Text] [Related]
13. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
14. Molecular Analysis of Ganciclovir-Resistant Cytomegalovirus in Renal Transplant Recipients with High Viral Load.
Sohrabi M; Behzadian F; Hosseini SM; Lashini H
Arch Iran Med; 2016 Oct; 19(10):700-703. PubMed ID: 27743434
[TBL] [Abstract][Full Text] [Related]
15. Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens.
Daikoku T; Saito K; Aihara T; Ikeda M; Takahashi Y; Hosoi H; Nishida T; Takemoto M; Shiraki K
Microbiol Immunol; 2013 May; 57(5):396-9. PubMed ID: 23668613
[TBL] [Abstract][Full Text] [Related]
16. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
Boutolleau D; Deback C; Bressollette-Bodin C; Varnous S; Dhedin N; Barrou B; Vernant JP; Gandjbakhch I; Imbert-Marcille BM; Agut H
Antiviral Res; 2009 Feb; 81(2):174-9. PubMed ID: 19063923
[TBL] [Abstract][Full Text] [Related]
17. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
[TBL] [Abstract][Full Text] [Related]
18. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
19. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
Campos AB; Ribeiro J; Boutolleau D; Sousa H
Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
[TBL] [Abstract][Full Text] [Related]
20. Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
Fischer L; Sampaio KL; Jahn G; Hamprecht K; Göhring K
J Clin Virol; 2015 Aug; 69():150-5. PubMed ID: 26209398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
